PO Box 824
New South Wales
About NoxopharmNoxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.
Founder and CEO: Graham Kelly
Please click here for clinical trial information.
15 articles with Noxopharm
Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda ® , to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo ® ) in the treatment of cancer. Veyonda is a first-in-class sphingosine-1-phosphate inhibitor with h
As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda ® , in the Company’s Phase 1 NOXCOVID-1 study. NOXCOVID-1 is looking at treating those COVID-19 patients hospitalize
Noxopharm , a clinical-stage Australian oncology drug development company listed on the ASX (ASX:NOX), has claimed a breakthrough in the search for restoring immune function within “cold” microtumors, converting them to so-called “hot” tumors. The breakthrough stems from new preclinical data from two independent research groups. The data confirms that idronoxil, the active ingredient in the company’s immuno-oncology drug ca
Noxopharm, a clinical-stage Australian drug development company, has announced commencement of its NOXCOVID clinical program with a planned Phase I trial in Europe.
At the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, Noxopharm , a clinical-stage Australian oncology drug development company, has reported two sets of clinical data relating to the development of NOX66 ( Veyonda ® ) as a treatment for end-stage cancer. The posters addressed how NOX66 may improve treatment responses in men with mCRPC and also its contribution to restoring sensitivity to apop
Noxopharm , a clinical-stage Australian oncology drug development company, has announced the details of the radiographic review of its DARRT-1 clinical study and is pleased to report a 27% incidence of abscopal response in soft tissue lesions using a combination of Veyonda® and low-dose radiotherapy. An abscopal response, a highly prized clinical response, involves radiation directed at a single tumor which triggers resulting
Noxopharm, a clinical-stage Australian oncology drug development company, has identified a clinical trial opportunity that could help reduce the mortality rate of COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
Feb. 25, 2020 13:30 UTC FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda ® Current IND for sarcoma paves the way for future INDs for late-stage prostate cancer SYDNEY--( BUSINESS WIRE )-- Noxopharm (ASX: NOX) announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Veyonda ® for combination treatment with doxorubicin in patients with soft tissue sarcomas. “Based on preclinical an
Noxopharm (ASX: NOX), an Australian drug development company, reports positive end-of-study data from its DARRT-1 Phase 1b trial.
Noxopharm is pleased to announce that it has appointed Mr Alexander Hunter as its Chief Commercial Officer.
Noxopharm (ASX: NOX) announces that it will apply its glutamate-inhibition technology to the treatment of glioblastoma multiforme (GBM).
4/26/2019Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.